(Q41920366)

14 October 2017

title

MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. (English)

1 reference

14 October 2017

Qi L

1

1 reference

14 October 2017

Ostrand-Rosenberg S

series ordinal

2

1 reference

14 October 2017

language of work or name

1 reference

1 February 2000

1 reference

14 October 2017

1 reference

14 October 2017

volume

1

1 reference

14 October 2017

issue

2

1 reference

14 October 2017

page(s)

152-160

1 reference

T cell defined tumor antigens

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Cell-based vaccines for the stimulation of immunity to metastatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Tumor antigen presentation: changing the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Mechanisms of antigen uptake for presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Endogenous antigen presentation by MHC class II molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Assembly of an abundant endogenous major histocompatibility complex class II/peptide complex in class II compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

MHC class II-associated invariant chain contains a sorting signal for endosomal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Relationship between invariant chain expression and major histocompatibility complex class II transport into early and late endocytic compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Antigen processing and presentation by the class I major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Mechanisms of MHC class I--restricted antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Class II transactivator regulates the expression of multiple genes involved in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

The modification and assembly of proteins in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

A segment of the MHC class II beta chain plays a critical role in targeting class II molecules to the endocytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Truncation of the class II beta-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H-2M complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

LacZ inducible, antigen/MHC-specific T cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

A proteolytic system that compensates for loss of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Tumor antigens recognized by T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

The role of CD4+ T cell responses in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0854.2000.010207.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1034/J.1600-0854.2000.010207.X

1 reference

14 October 2017

1 reference